RECRUITING

Vasodilator and Exercise Study for DMD (VASO-REx)

Description

Examining two strategies as potential adjuvant therapies for Duchenne muscular dystrophy (DMD); aerobic exercise training (to induce adaptations in skeletal muscle and improve cardiovascular health) and tadalafil, an FDA-approved vasodilator (to optimize blood flow and muscle perfusion which is impaired and often overlooked in DMD). Target: improved muscle function, vascular health, and DMD treatment.

Conditions

Duchenne Muscular DystrophyDuchenne DiseaseMuscular DystrophyMuscular Dystrophy in ChildrenVasodilationExerciseDMD
Talk to us

Related Conditions:

Duchenne Muscular DystrophyDuchenne DiseaseMuscular DystrophyMuscular Dystrophy in ChildrenVasodilationExerciseDMD

Study Overview

On this page

Study Details

Study overview

Examining two strategies as potential adjuvant therapies for Duchenne muscular dystrophy (DMD); aerobic exercise training (to induce adaptations in skeletal muscle and improve cardiovascular health) and tadalafil, an FDA-approved vasodilator (to optimize blood flow and muscle perfusion which is impaired and often overlooked in DMD). Target: improved muscle function, vascular health, and DMD treatment.

Vasodilators and Exercise as Adjuvant Therapy for Duchenne Muscular Dystrophy (VASO-REx Study)

Vasodilator and Exercise Study for DMD (VASO-REx)

Condition
Duchenne Muscular Dystrophy
Intervention / Treatment

-

Contacts and Locations

Gainesville

University of Florida Clinical and Translational Research Building, Gainesville, Florida, United States, 32603

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Diagnosis of DMD confirmed by genetic report
  • * Minimum entry age of 6.0 years old
  • * Ambulatory
  • * On stable glucocorticoid regimen (for \> 3 months)
  • * Contraindication to a Magnetic resonance Imaging examination (e.g. severe claustrophobia, magnetic implants, unable/unwilling to perform test)
  • * Presence of unstable medical problems, including severe cardiomyopathy, left ventricular ejection fraction \<45%, cardiac conduction abnormalities as evidenced on ECG, uncontrolled seizure disorder, uncontrolled hypo or hypertension
  • * Presence of a secondary condition that impacts muscle function or muscle metabolism (e.g., myasthenia gravis, endocrine disorder, mitochondrial disease)
  • * Presence of a secondary condition leading to developmental delay or impaired motor control (e.g., cerebral palsy) or previous history of unprovoked rhabdomyolysis
  • * Contraindications to phosphodiesterase 5 inhibitors (use of nitrates, alpha-adrenergic blockers, other phosphodiesterase 5 inhibitors) or other medications known to modulate blood flow or muscle metabolism
  • * Participation in currently approved FDA trials or other investigational clinical trials during the period of the study

Ages Eligible for Study

6 Years to

Sexes Eligible for Study

MALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Florida,

Tanja Taivassalo, Ph.D., PRINCIPAL_INVESTIGATOR, University of Florida, College of Medicine, Department of Physiology and Aging

Study Record Dates

2026-11